Dataset opportunity
Dicentra — 可下载数据资产机会
Dicentra 持有的可下载大型数据资产，可用于微调和预训练。
Score
67.9
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
73%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
全球药物警戒市场在 2025 年估值为 93.5 亿美元，预计复合年增长率为 14.69%（来源：Fortune Business Insights）。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-07-30
Agitazione psicomotoria in emergenza: Fimeuc propone un tavolo tecnico per un protocollo unico nazionale
tecnicaospedaliera.it ↗ - 📰press2026-07-30
Oltre la Brexit: opportunità e sfide del mercato UK per i dispositivi medici
distrettobiomedicale.it ↗ - 📰press2026-07-30
Gemeinsame Begriffe für Gesundheitsdaten aus der Stimme
devicemed.de ↗ - 📰press2026-07-30
MTAA Members Update | 31 July 2026
mtaa.org.au ↗ - 📰press2026-07-23
Intelligence26: AI and the Future of Practice
ranzcr.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
可下载数据资产
Modality
表格
Sector
医疗保健
Volume
大型
Freshness
定期
Rarity
中等
Accessibility
受限
Legal
混合所有权 — GDPR 敏感（PII 审查）
Buyer persona
领域 LLM 构建者和垂直 AI 初创公司
Dicentra 持有一个来自其医疗保健领域活动的实质性表格数据资产，包括临床试验和药物警戒的`检查记录`、`医疗记录`和`监管`文件。此结构化、多来源的数据集非常适合用于大型语言模型的微调，以应用于专业的生命科学领域，例如增强药物安全分析和简化监管合规报告。
商业价值锚定在全球药物警戒市场，该市场在2025 年估值为 93.5 亿美元，预计将以14.69% 的复合年增长率增长。尽管由于二次使用需要多方同意、临床试验中高度敏感的个人身份信息 (PII) 以及严格的监管监督，访问要求复杂，但对此类可下载数据资产的高增长需求使其成为寻求竞争优势的 AI 买家的稀有且宝贵的资源。⚠ 尽职调查（有价值的数据，可协商访问）：数据主要为生命科学客户生成，需要复杂的多方同意才能二次使用；涉及临床试验和药物警戒的高度敏感健康数据 (PII)；FDA 和加拿大卫生部的监管限制，涉及数据完整性和报告。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明了持有方拥有其在医疗保健咨询核心业务中的专有数据，特别是在药物警戒和临床试验支持方面。该数据集包含有关不良事件报告、监管流程和毒理学风险评估的结构化信息。对于垂直 AI 初创公司而言，这是微调领域特定 LLM 的关键资产，可用于自动化和改进药物安全监控，这是全球药物警戒市场的一个关键功能，预计该市场将以每年近 15% 的速度增长。
See dimension details ↓- Dataset Specificity90
主导的“下载”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
专有领域数据（开放降低稀有度）
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume94
10 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/开放（当前）
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适合微调
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand85
AI 买家需求旺盛，这得益于药物警戒市场的显著增长，该市场正以 14.69% 的复合年增长率扩张，因为公司越来越多地采用 AI 来增强药物安全和监管合规性。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
开放/API 访问
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength100
5 种证据类型，10 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
所有权=混合，许可=gdpr_敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 个数据胃口信号（0 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
盈余=中等，5 个近期外部信号 — 专有数据超出已货币化的范围
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ 良好目标 — Dicentra 是一家合同研究和咨询公司，其核心业务是提供监管和合规服务，这会产生有价值的临床试验和产品数据作为副产品，使其成为一个好的目标。问题：主要问题是确定在客户项目（临床试验、监管提交）期间生成的数据的所有权，以及 Dicentra 是否保留；有一个名为“Dicentra Pension Services, LLC”的独立收购实体，不应与目标公司混淆。[7]；还有一个名为“Dicentra”的植物属，会污染搜索结果。[5, 8, 9, 11]
- Deep Qualification90
⚠ 需要审查 — Dicentra 是一家合同研究组织 (CRO)，其业务是提供监管和临床试验服务；它处理的数据归其客户所有且受到严格限制，这使得在当前结构下数据资产机会不可行。[数据归公司客户所有；许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Downloads / exports
这些证据指向一个表格数据集，其中包含已注册访问专业医疗保健监管资源的专业联系人，为行业潜在客户和意向数据提供了宝贵的来源。
Knowledge base / docs
持有方拥有一个知识库，详细说明了监管合规和毒理学风险评估的流程，这对于训练 AI 理解和自动化化学危害分类至关重要。
Medical records / imaging
这表明存在与不良事件评估、分类和病例报告相关的结构化记录，这是任何专注于药物警戒的 AI 的核心组成部分。
Regulatory records
该公司从 I-IV 期临床试验的定制生物统计学分析中生成数据，这是预测试验结果或优化研究方案的模型的宝贵资产。
Inspection reports
这指向了详细说明医疗保健产品市场准入要求和策略的文档，对于能够导航全球监管途径的 AI 系统很有用。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Dicentra Downloadable Data — a Large downloadable data asset (Tabular modality) in the healthcare domain. Primary AI use-case: Fine Tuning. Market signal: Global Pharmacovigilance market was valued at $9.35 billion in 2025, projected to grow at a 14.69% CAGR (source: Fortune Business Insights).. Investment score 67.9/100 (confidence 0.73). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Cornishlithium — 工业运营数据集机会
View opportunity →其他Redhawkgroup — 检验报告数据集机会
View opportunity →工业Optimach — 工业传感器数据集机会
View opportunity →